Veeva Systems FCF Margin
The Free Cash Flow Margin of Veeva Systems (VEEV) as of Jul 25, 2026 is 43.38 %. In the previous year, Free Cash Flow Margin was 38.94 % — a change of 11.40% (higher).
Get this data via API
Financial Data API
FCF Margin
43.38 %
YoY
11.40%
Last updated:
Free Cash Flow Margin of Veeva Systems is 2026 43.38 % . Free Cash Flow Margin of Veeva Systems was 2025 38.94 % . It decreases by 11.40% higher compared to the previous year.
Access this data via the Eulerpool API
Veeva Systems Stock analysis
What does Veeva Systems do? The history of Veeva Systems Inc:
Veeva Systems is a leading company in the field of cloud software for the life science industry. The company was founded in 2007 and is headquartered in Pleasanton, California. Veeva was created by Peter Gassner and Matt Wallach to improve the management of clinical trials and collaboration in the pharmaceutical industry.
Business model of Veeva Systems Inc:
The business model of Veeva Systems is focused on improving efficiency and collaboration in the life science industry. The company offers cloud-based software solutions tailored to the needs of life science companies. These solutions include CRM systems, clinical trial management software, data management tools, and analytics tools.
Veeva Systems was founded as a CRM company for the life science industry. With its first software, Veeva CRM, the company revolutionized how pharmaceutical companies manage and collaborate with their sales forces. Since then, Veeva Systems has expanded its portfolio and offers a wide range of software solutions, ranging from planning and conducting clinical trials to collecting and analyzing data.
Divisions of Veeva Systems Inc:
Veeva Systems is divided into three divisions:
1) Commercial Cloud: This division of Veeva Systems provides software solutions for managing customer relationships, sales and marketing activities, and digital marketing for life science companies.
2) Vault: The Vault division of Veeva Systems offers software solutions for managing content, data, and processes involved in clinical trials and other research projects.
3) Data Cloud: This division offers analytics and data management tools that enable life science companies to collect, manage, and analyze their data.
Products of Veeva Systems Inc:
Veeva CRM: A CRM software solution that allows pharmaceutical companies to control and manage their sales and marketing activities.
Veeva Vault: A suite of software solutions that facilitate the management of clinical trials and research projects. Vault provides solutions for electronic data capture, electronic informed consent forms (eICFs), clinical data management, and document management.
Veeva Network: A cloud-based platform that enables life science companies to simultaneously collect patient data and advertise for it.
Veeva OpenData: A database of contacts and companies from the life science industry that is regularly updated.
Veeva Align: A tool for optimizing personnel deployment and ensuring compliance in the sales of life science companies.
Veeva Vault QualityOne: A platform for managing quality control processes, including supply chain monitoring, compliance with regulations, and ensuring standards.
Conclusion:
Veeva Systems has positioned itself as a leading provider of cloud software solutions for the life science industry and offers its portfolio of CRM, clinical trial management, data management, and analytics tools. The company has succeeded in improving collaboration in the pharmaceutical industry by leveraging cloud technologies to increase effectiveness, safety, and compliance. Veeva Systems is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Veeva Systems stock
Free Cash Flow Margin of Veeva Systems is 43.38 % in 2026.
Access this data via the Eulerpool API
Margins — Veeva Systems
All Key Metrics — Veeva Systems
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth